key: cord-0790258-xbx01g4x
authors: Rima, Mariam; Rima, Mohamad; Fajloun, Ziad; Sabatier, Jean-Marc; Bechinger, Burkhard; Naas, Thierry
title: Antimicrobial Peptides: A Potent Alternative to Antibiotics
date: 2021-09-10
journal: Antibiotics (Basel)
DOI: 10.3390/antibiotics10091095
sha: 37d32fd81e0af2906188d0da2a8505d31c0c67b2
doc_id: 790258
cord_uid: xbx01g4x

Antimicrobial peptides constitute one of the most promising alternatives to antibiotics since they could be used to treat bacterial infections, especially those caused by multidrug-resistant pathogens. Many antimicrobial peptides, with various activity spectra and mechanisms of actions, have been described. This review focuses on their use against ESKAPE bacteria, especially in biofilm treatments, their synergistic activity, and their application as prophylactic agents. Limitations and challenges restricting therapeutic applications are highlighted, and solutions for each challenge are evaluated to analyze whether antimicrobial peptides could replace antibiotics in the near future.

There was collective enthusiasm about the advent of antibiotic therapy, and this optimism prevailed in the light of the constant discoveries of new classes of antibiotics, despite the very early description of therapeutic failures and resistance to treatments with these drugs [1] . At the present, in 2021, multidrug-resistant (MDR) and even pandrug-resistant (PDR) bacteria have spread widely around the world and are currently responsible for increasing morbidity and mortality rates, as well as the significant cost to society [2] . The low frequency of discoveries of new classes of antibiotics, and the rapid emergence of resistance to novel antibiotics, show the need for novel therapeutic alternatives to antibiotics, such as lysine-based small molecules, vaccines, anti-virulence strategies, phage therapy and antimicrobial peptides.

Antimicrobial resistance (AMR) is an emerging global health problem that results, in some cases, in difficulties to treat bacterial infections. It was listed by the World Health Organization (WHO) among the top ten global public health threats facing humanity, as it is predicted to cause about 10 million deaths each year by 2050 [3] . Therefore, efforts to slow down the propagation of AMR have been implemented worldwide. As such, a Global Action Plan on Antimicrobial Resistance (GAP) was created in 2015, aiming to implement national action plans to limit the progress of AMR. In addition, the WHO reports call different models, as recently reviewed in Huan et al. [7] . (i) The "barrel-stave" model indicates that peptides insert into the membrane and direct their hydrophobic regions toward the lipid core of the bilayer, forming a transmembrane pore. Experimental evidence for this model has been obtained from structural and biophysical investigations of very hydrophobic sequences, some being devoid of any charge [18] . (ii) The "carpet" model suggests that AMPs accumulate parallel to the membrane surface, forming a "carpet" [19] . Once a threshold concentration of peptides has been reached, they exert a "detergent" effect, leading to the rupture of the cell membrane. Extensive experimental evidence for this mechanism has been obtained for many cationic amphipathic peptides such as magainins [20] . (iii) The "toroidal pore" model implies that AMPs insert themselves perpendicularly into the membrane through interactions between the lipid bilayer and the hydrophilic region of the peptides. In doing so, the membrane distorts and thus forms a "toroidal pore" [21] . (iv) The "aggregate" model assumes the formation of aggregates of peptides and lipids, allowing the translocation of AMPs across membranes. When considering these models, it should be kept in mind that on the one hand, lipid bilayers are soft and can adapt their shapes and thicknesses to the membrane-inserted peptides. On the other hand, the peptides cover a highly dynamic and flexible conformational space and upon interaction with the membrane also respond. Thereby, many different supramolecular arrangements can be formed depending on the lipid composition, peptide concentration, salt, and buffer. These considerations have been incorporated into the SMART model, which takes into consideration that peptides and lipids adjust their conformation and shape when interacting with each other thereby covering a full range of possibilities of interactions between AMPs and membranes [22] . The bacterial membrane is the most important target of AMPs as they act by disrupting the integrity of the pathogen's membrane [17] . Several models have been described in the literature, all of which result in osmotic lysis. Membrane disruption may happen through different models, as recently reviewed in Huan et al. [7] . (i) The "barrel-stave" model indicates that peptides insert into the membrane and direct their hydrophobic re- 

Some peptides cross the cytoplasmic membrane and target cellular processes essential for the survival of the pathogen, including inhibition of DNA replication, protein synthesis, interference with nucleic acid biosynthesis, metabolism, cell division, cell wall, and LPS binding proteins [23] .

Indeed, some cationic AMPs have been shown to complex and flocculate nucleic acids or other anionic macromolecules due to their affinity for negatively charged phosphodiester bonds [24, 25] . For example, Frenatin 2.3S internalizes within bacterial cells after destabilizing their membranes and can bind nucleic acids [26] . Others are able, even at low concentrations, to affect protein synthesis. The examples are countless; for instance, tryptophan-containing AMPs were proven to be efficient at killing Pseudomonas aeruginosa by down-regulating the expression of DNA replication-initiating genes [27] . In addition, Tur1A, an AMP found in dolphins, binds to ribosomes, and blocks the translation of mRNA into proteins [28] . Thanatin, an insect-derived AMP targets the bacterial LPS and induces the LPS-mediated aggregation [29] . Tridecaptin blocks ATP synthesis in bacteria and is active on MDR and colistin-resistant Enterobacterales [30] .

Well characterized for their antimicrobial activities, AMPs are also known for their immunoregulatory functions. They can thus participate in the recruitment and activation of immune cells.

It has been described in the literature that certain AMPs, such as defensins, can enhance the production of inflammatory cytokines, such as interleukin-1 [31] . To mention another example, cathelicidin BF has been shown to exhibit immunomodulatory activity that, in mice, is able to ameliorate pneumonia caused by Pseudomonas aeruginosa [32] .

When in the form of biofilms, pathogens escape more easily the action of conventional antimicrobials. Indeed, microorganisms in biofilms are capable of tolerating, in particular, via transcriptional regulatory mechanisms, high concentrations of antimicrobials even though they are totally sensitive in planktonic conditions [33] .

The mode of action of AMPs on biofilms is not yet fully understood; however, it is recognized that they can prevent different stages of biofilm formation. It has been shown that some AMPs can inhibit the adhesion of bacteria to surfaces by reducing certain types of motilities such as "swarming" or "swimming". They are also able to stimulate "twitching", another type of motility known to promote the disassembly of biofilms. AMPs can also down-regulate certain genes involved in quorum sensing, the latter being known to play a role in biofilm formation and/or in the organization and communication of bacteria within the biofilm [34] . Thus, it has been demonstrated that LL-37 cathelicidin targets quorum sensing mechanisms that control P. aeruginosa biofilm formation [35] .

Several advantages were observed for AMPs over classical antibiotics: (i) usual resistance mechanisms observed toward conventional antibiotics are bypassed by AMPs [36, 37] ; (ii) they are easier to synthesize since they consist usually of short amino acid sequences [38] ; (iii) they show rapid killing [39] ; (iv) they act on bacteria irrespective of their resistance phenotype, since they are not affected by the known resistance mechanisms [40] [41] [42] , and (v) they do not affect microbiota, which are often disrupted by conventional antibiotics [43] . These advantages made it possible to have several AMPs that are now in medical use, such as nisin, gramicidin, polymyxins, daptomycin, and melittin (reviewed by Dijksteel et al. [44] ).

Hundreds of AMPs have shown antibacterial activity against resistant bacteria in vivo [45] . Among the most recent examples, a novel piscidin-like peptide called cerocin from black sea bass fish was described to exert broad-spectrum antimicrobial activity against several bacteria, especially Gram-positive pathogens [46] . Similarly, jelleine-I, a small AMP formed by eight amino acids, acts against both Gram-negative and Gram-positive bacteria, mainly by disrupting the integrity of the cell membrane [47] . Furthermore, another novel defensinlike peptide was described recently for its antimicrobial activity against Gram-positive bacteria, including Staphylococcus aureus, Staphylococcus carnosus, Nocardia asteroides, and one tested Gram-negative bacterium Psychrobacter faecalis [48] . Interestingly, AMPs can act against bacteria of the ESKAPE complex, which is made up of six pathogens responsible for most of the nosocomial life-threatening infections: Enterococcus faecium, S. aureus, Klebsiella pneumoniae, Acinetobacter baumannii, P. aeruginosa, and Enterobacter spp. [49] . ESKAPE pathogens are usually MDR, which limits therapeutic options and puts patients' lives at risk. Many AMPs showed promising activity against ESKAPE pathogens. For example, bip-P-113, dip-P-113 and nal-P-133 are three derivatives of the AMP p-133, that work well against E. faecium, showing a low MIC of 4 µg/mL as compared to 64 µg/mL for vancomycin [50] .

The resistance of S. aureus to methicillin remains a huge drawback associated with high mortality rates [51] . Many AMPs are able to eradicate methicillin-resistant S. aureus (MRSA) [52] ; for example, poly(2-oxazoline)s, an easy-to-synthesize polymer mimetic of AMPs that displays high and selective antimicrobial activity against MRSA, is considered as a promising antimicrobial candidate due to its low MIC values (12.5 µg/mL) [53] . ∆M3 is a novel synthetic peptide consisting of a short amino acid sequence that has low toxicity coupled to a great biological activity, especially against S. aureus strains. The low MICs of ∆M3 (5 µg/mL) against S. aureus (ATCC25923) and MRSA (7.5 µg/mL) [54] , make it a great AMP candidate. Finally, SAAP-148, a derivative of the human LL37 peptide, is active against several resistant ESKAPE pathogens (S. aureus, P. aeruginosa, A. baumannii), including biofilms that occur in wound infections [55] .

K. pneumoniae, is a challenging bacterium with respect to conventional antibacterial therapy, as it may be encapsulated, limiting the antibiotic's capacity to penetrate. However, this bacterium is sensitive to pepW, an AMP that targets, aggregates and disrupts K. pneumoniae's capsules with low MICs (2-4 µg/mL) [56] . PepW is also active against Escherichia coli with even lower MICs of 1-2 µg/mL [56] . Similarly, AA139 and SET-M33 may be promising novel drugs against MDR K. pneumoniae strains with MICs ranging from 4 to 16 µg/mL, but more interestingly, they remained active even on colistin-resistant K. pneumoniae isolates [57] . Aurein 1.2, CAMEL, citropin 1.1, LL-37, Cec4 and omiganan have shown excellent activity against A. baumannii, with MICs going from 2 to 16 µg/mL [58, 59] . Consequently, AMPs are considered as potential candidates for new treatments since they have relatively low MICs against a bacterial strain for which only limited, if any, treatment options are available. As reviewed by Neshani et al., 46 AMPs exhibit good activity against A. baumannii, some of which could be used as preventive and others as therapeutic options [60] . DN4 and DC4 have shown significant activity against A. baumannii as well as in a K. pneumoniae model, where an MIC of 32 µg/mL was noted [61] .

On the other hand, ZY4 permeabilizes the MDR P. aeruginosa membrane and exhibits killing with MICs ranging from 2 to 4.5 µg/mL [62] . GL13K was also described as an active AMP showing good activity against MDR P. aeruginosa, with an MIC of 8 µg/mL [63, 64] . Furthermore, NCK-10 is a small molecule mimetic made of a naphtalene aromatic ring, a decyl chain and a cationic lysine with potent P. aeruginosa antibiofilm activity [65] .

To date, and according to the AMPs database, 47 of the listed AMPs show synergistic activities against several pathogens. This synergistic/additive effect is of interest to find 

Another potential domain of action of AMPs is preventive healthcare, which deals with the prevention of illness [78] . As such, polycationic peptides were used as prophylactic agents against methicillin-susceptible or methicillin-resistant Staphylococcus epidermidis [79] . Antibacterial peptide-based gels were also synthesized to prevent medical implanted device infections [80] . Likewise, coating antimicrobial peptides was used for the prevention of urinary catheter-associated infections [81] . For example, bactericidal activity of chain 201D, an AMP derived from crowberry endophytes, was effective against E. coli and S. aureus, when immobilized on a model surface where it can bind and kill, by contact, a high percentage of adherent bacteria [81] . This gives AMPs a high potential for the development of antimicrobial surfaces, namely for application in urinary catheters [81] . Another example of AMP-based infection prevention in healthcare is dental caries caused by several pathogens [82] . Some AMPs including α-helical ones prevent bacterial adherence to implant surfaces [83] .

Biofilms are one of the most common spreaders of infectious disease [84] . They form when communities of microorganisms adhere to some surfaces, and they are usually hard to treat [85] . Biofilms can develop on catheters, breast implants, or even on living tissue such as lungs or teeth, putting patients at risk of developing nosocomial infections that are difficult to eradicate with antibiotics [86] . By living in biofilms, bacteria are protected from harmful conditions, and thus can develop resistance to common antibiotics, which makes AMPs promising alternatives for new therapeutic strategies [87, 88] . In this context, Antibiotics 2021, 10, 1095 7 of 15 as already reviewed by Galdiero et al., many AMPs serve as agents that interfere with bacterial biofilm formation/expansion [89] , inhibit bacterial adherence on indwelling medical devices, and therefore can reduce nosocomial infections [81, 90] . For example, vancomycin-coated tympanostomy tubes resist MRSA biofilm formation [91] . Interestingly, another AMP of the cathelecidins family D-LL-31 greatly enhances the biofilm-eradicating effects of currently used antibiotics [92, 93] . Furthermore, SAAP-148, a synthetic AMP, showed great antibiofilm activity, where it eradicates MRSA and MDR A. baumannii [55] . Similarly, KKd-11 is a remarkable AMP that was not only able to inhibit the formation of biofilms but also effectively kill the bacteria within the biofilms [94] . Together, these findings show interesting potential of AMPs, which is a step forward as compared to conventional antibiotic therapy.

In the context of the preventive healthcare field, AMPs could also be used as vaccines or vaccine adjuvants to induce protective immunity or immune response against infections [95] . As such, IC31, a synthetic adjuvant containing the AMP KLKL5KLK, can induce a protective immune response against the desired antigen [96] . It was also proven to be a potent adjuvant to a DNA vaccine targeting Mycobacterium tuberculosis [95] . However, no vaccine exists until today against MDR bacterial isolates [97] . Therefore, in this present scenario of exponentially increasing AMR, using the immuno-modulatory advantages of AMPs could help in alleviating AMR problem. The development of AMP-based vaccines may be able to reduce the burden and to overcome the AMR issue worldwide [98] .

Rapid diagnostic tools are the key to prevent the spread of contagious infectious agents by rapidly identifying carriers or infected patients and prompt implementation of adapted infection control measures. The ability of AMPs to sense bacterial presence in potentially infected clinical samples is a major advantage. As already reviewed by Pardoux et al., AMPs could serve as infection selective tracers where they act as probes in biosensors and thus detect pathogens [99] . This is due to the preferential binding of AMPs along with their great number allowing the coverage of a wide range of microorganisms. AMPs were also described as powerful radiotracers and proved to be even better than labeled antibiotics [100] . [99mTc-HYNIC/EDDA]-MccJ25 is an example of an antimicrobial peptide analog that was used as a potential radiotracer for detection of infection [99] . Interestingly, this imaging agent for E. coli infection is also stable against enzymatic and metabolic degradation [101] .

In addition to activity toward bacteria, according to the database of antimicrobial activity and structure of peptides (DBAASP) [102] ., 208 AMPs have been reported to show antiviral activities against SARS-CoV-2. Slight changes to glycocin F and lactococcin G increased their efficacy against SARS-CoV-2 by inhibiting protein synthesis with no side effects [103] . Similarly, mucroporin-M1 (LFRLIKSLIKRLVSAFK), a peptide analog displaying four amino acid changes (G3R, P6K, G10K, and G11R) as compared to the parent peptide mucroporin shows therapeutic activities against SARS-CoV-2 [104] . Brilacidin and LF are additional drug candidates for SARS-CoV-2 treatment [105, 106] . Caerin 1.6 and caerin 1.10, two other AMPs, have a very high potential to interact with the spike surface protein of SARS-CoV-2, but low affinity for the ACE2 receptor. The selectivity of these peptides toward viral proteins makes them potential candidates for SARS-CoV-2 therapy [107] .

Despite the numerous advantages of AMPs, several problems prevented them from being used as therapeutic agents in human clinics. For instance, one major problem is their limited stability, especially their susceptibility to the degradation by proteases [108, 109] . In fact, the instability toward proteases hampers the development of many AMPs [110] , by limiting their use for topical applications and/or requiring sequence modifications, to make them less susceptible to degradation [111] . Other problems include high extraction costs [112, 113] , poor bioavailability [6] , short half-lives [114] , cytotoxicity, and lack of specificity [115, 116] . In addition, AMPs tend to display lower direct antimicrobial activity as compared to antibiotics. In real, regulatory agencies want AMPs to exhibit similar or even stronger activities than antibiotics [37] . Finally, resistance development by the bacteria toward AMPs cannot be excluded, especially if the microorganism is often exposed to them [117] . So far, only a few resistance mechanisms to AMPs have been described, including sequestration by bacterial enzymes and export by efflux pumps [118] . Taken together, these limitations slow down the successful reach of AMPs into clinical phases and limit their use to a small fraction of their potential (Figure 2 ) [44] .

these peptides toward viral proteins makes them potential candidates for SARS-CoV-2 therapy [107] .

Despite the numerous advantages of AMPs, several problems prevented them from being used as therapeutic agents in human clinics. For instance, one major problem is their limited stability, especially their susceptibility to the degradation by proteases [108, 109] . In fact, the instability toward proteases hampers the development of many AMPs [110] , by limiting their use for topical applications and/or requiring sequence modifications, to make them less susceptible to degradation [111] . Other problems include high extraction costs [112, 113] , poor bioavailability [6] , short half-lives [114] , cytotoxicity, and lack of specificity [115, 116] . In addition, AMPs tend to display lower direct antimicrobial activity as compared to antibiotics. In real, regulatory agencies want AMPs to exhibit similar or even stronger activities than antibiotics [37] . Finally, resistance development by the bacteria toward AMPs cannot be excluded, especially if the microorganism is often exposed to them [117] . So far, only a few resistance mechanisms to AMPs have been described, including sequestration by bacterial enzymes and export by efflux pumps [118] . Taken together, these limitations slow down the successful reach of AMPs into clinical phases and limit their use to a small fraction of their potential (Figure 2 ) [44] . 

Although a huge number of AMPs have been described, very few reach the market. For example, ghrelin, the endogenous appetite peptide, possessing a good antimicrobial activity against Gram-negative bacteria is still in phase II clinical trial [119, 120] . Surotomycin, is another example of AMP that is currently under investigation in phase III clinical trials; it targets Clostridium difficile and treats the associated diarrhea. The examples are countless; many AMPs remain under investigation until their efficacy is confirmed and secondary effects are eliminated. Some AMPs fail to reach the last clinical trials, such as (i) frulimicin B, which was terminated after phase I clinical trial due to unfavorable pharmacokinetics [44] and (ii) murepavadin, which was eliminated after a phase III clinical trial since it causes acute kidney injuries [44] .

Different strategies were explored to overcome the drawbacks described previously. Modifications such as encapsulation of AMPs could be the key to avoiding their degradation by proteases and thus improving stability [121, 122] . Several AMPs have been tested before and after encapsulation, and an obvious enhancement was observed: encapsulation of the AMP IK8, with gold nanorods into polyethylene glycol hydrogels protected the 

Although a huge number of AMPs have been described, very few reach the market. For example, ghrelin, the endogenous appetite peptide, possessing a good antimicrobial activity against Gram-negative bacteria is still in phase II clinical trial [119, 120] . Surotomycin, is another example of AMP that is currently under investigation in phase III clinical trials; it targets Clostridium difficile and treats the associated diarrhea. The examples are countless; many AMPs remain under investigation until their efficacy is confirmed and secondary effects are eliminated. Some AMPs fail to reach the last clinical trials, such as (i) frulimicin B, which was terminated after phase I clinical trial due to unfavorable pharmacokinetics [44] and (ii) murepavadin, which was eliminated after a phase III clinical trial since it causes acute kidney injuries [44] .

Different strategies were explored to overcome the drawbacks described previously. Modifications such as encapsulation of AMPs could be the key to avoiding their degradation by proteases and thus improving stability [121, 122] . Several AMPs have been tested before and after encapsulation, and an obvious enhancement was observed: encapsulation of the AMP IK8, with gold nanorods into polyethylene glycol hydrogels protected the AMP from proteolysis and provided a triggered release of the therapeutic molecule [123] . High extraction costs could be limited by synthesizing AMPs in the lab using natural ones as templates where, at the same time, synthetic AMPs are always an enhanced version of the natural ones [124] . For this, genetic programming could be used to save not only money, but also on time and workload, and this could be started in silico through programs that predict the activity of AMPs before even generating them to avoid unnecessary synthetic efforts [125] . To improve bioavailability, increased half-lives of AMPs, and reduced cytotoxicity, structural modifications such as dimerization [126] , methylation and Antibiotics 2021, 10, 1095 9 of 15 more have been successfully tested [127] . Specificity could be introduced by strategies for site specific release [128] , such as specifically targeting AMPs (STAMP), which showed high efficiency in delivering the AMP to the target without harming the natural microbiota [129, 130] . This strategy aims to implant AMPs into a drug delivery vehicle composed of the AMP itself in addition to a targeting peptide that allows a specific binding to the desired pathogen [43, 129] .

For decades, research for AMPs was not always successful. As mentioned previously, some AMPs were not introduced into clinics due to their toxicity/ degradation, while others were not very performant. However, none of these efforts were lost as these AMPs played the role of templates for the development of more efficient agents. For example, the introduction of L-phenylalanine into protonectin enhanced its selective antibacterial activity against several Gram-positive bacteria and reduced MIC in S. aureus from 16 to 4 µg/mL [131] . In addition, the cathelicidin-derived antimicrobial peptide PMAP-23 was further modified by amino acid substitutions to obtain PMAP-23RI (for, Leu5-Arg and Thr19-Ile). The variant exhibited a higher stability and improved antibacterial activity when compared with the original PMAP-23, with MICs reduced by half in some cases from a simple modification to the original AMP [132] . Analogs of mastoparan-C were also designed by amino acid substitution and peptide truncation, which reduced cell toxicity and improved the bioactivity of the original AMP [127, 133] . Table 2 provides additional information on many AMPs discussed in this paper. Table 2 . Amino acid sequences, type of synthesis and target groups of the AMPs discussed in this paper. Data were retrieved from the database of antimicrobial activity and structure of peptides [102] . GP: Gram-positive bacteria; GN: Gram-negative bacteria. 

AMPs constitute promising agents with good antibacterial activity against a large set of pathogens, including Gram-negative and Gram-positive bacteria. Their ability to kill ESKAPE pathogens, especially those being pan-drug-resistant, represents a clinical added value over antibiotics due to the limited treatment options available to eradicate such infections. In this review, examples of AMPs effective against MDR bacteria that have the potential to replace conventional antibiotics have been reported. Their roles in boosting the activity of therapeutic molecules, eradication of biofilms, and preventive healthcare broaden AMPs' therapeutic potential (Figure 3 ). However, despite the huge number of AMPs described, and the efforts to optimize them, only a few reached advanced clinical trials. There are several challenges, such as their low stability, high extraction costs, and cytotoxicity, which need to be overcome so AMPs can be used in clinics. Nevertheless, due to increasing research efforts, it is expected that, hopefully, potent alternatives to antibacterial agents with the ability to eradicate untreatable life-threatening infections will be developed soon. 

AMPs constitute promising agents with good antibacterial activity against a large set of pathogens, including Gram-negative and Gram-positive bacteria. Their ability to kill ESKAPE pathogens, especially those being pan-drug-resistant, represents a clinical added value over antibiotics due to the limited treatment options available to eradicate such infections. In this review, examples of AMPs effective against MDR bacteria that have the potential to replace conventional antibiotics have been reported. Their roles in boosting the activity of therapeutic molecules, eradication of biofilms, and preventive healthcare broaden AMPs' therapeutic potential (Figure 3 ). However, despite the huge number of AMPs described, and the efforts to optimize them, only a few reached advanced clinical trials. There are several challenges, such as their low stability, high extraction costs, and cytotoxicity, which need to be overcome so AMPs can be used in clinics. Nevertheless, due to increasing research efforts, it is expected that, hopefully, potent alternatives to antibacterial agents with the ability to eradicate untreatable life-threatening infections will be developed soon. 

Production of extracellular penicillin-inactivating substances associated with penicillin resistance in Staphylococcus aureus

The negative impact of antibiotic resistance. Clinical microbiology and infection: The official publication of the European Society of Clinical Microbiology and Infectious Diseases

Tackling Drug-Resistant Infections Globally: Final Report and Recommendations; Government of the United Kingdom

Predicting drug resistance evolution: Insights from antimicrobial peptides and antibiotics

Multifunctional host defense peptides: Intracellular-targeting antimicrobial peptides

Antimicrobial Peptides: An Emerging Category of Therapeutic Agents

Antimicrobial Peptides: Classification, Design, Application and Research Progress in Multiple Fields

Antimicrobial Peptides Discovery, Design and Novel Therapeutic Strategies

The Antimicrobial Peptide Database

ADAPTABLE: A comprehensive web platform of antimicrobial peptides tailored to the user's research

Cathelicidins: Family of antimicrobial peptides. A review

Antimicrobial Peptides: Amphibian Host Defense Peptides

Antimicrobial peptides from fish

Insect Antimicrobial Peptides, a Mini Review

The antimicrobial peptides and their potential clinical applications

Antimicrobial Peptides: Diversity, Mechanism of Action and Strategies to Improve the Activity and

Alamethicin Supramolecular Organization in Lipid Membranes from (19)F Solid-State NMR

From "carpet" mechanism to de-novo designed diastereomeric cell-selective antimicrobial peptides

The mechanisms of action of cationic antimicrobial peptides refined by novel concepts from biophysical investigations

Describing the mechanism of antimicrobial peptide action with the interfacial activity model

The SMART model: Soft Membranes Adapt and Respond, also Transiently, in the presence of antimicrobial peptides

Intracellular Targeting Mechanisms by Antimicrobial Peptides

Histidine-rich designer peptides of the LAH4 family promote cell delivery of a multitude of cargo

Intracellular biomass flocculation as a key mechanism of rapid bacterial killing by cationic, amphipathic antimicrobial peptides and peptoids

Unveiling the Multifaceted Mechanisms of Antibacterial Activity of Buforin II and Frenatin 2.3S Peptides from Skin Micro-Organs of the Orinoco Lime Treefrog (Sphaenorhynchus lacteus)

Interactions of Designed Trp-Containing Antimicrobial Peptides with DNA of Multidrug-Resistant Pseudomonas aeruginosa

The Dolphin Proline-Rich Antimicrobial Peptide Tur1A Inhibits Protein Synthesis by Targeting the Bacterial Ribosome

An Emerging Host Defense Antimicrobial Peptide with Multiple Modes of Action

New Variant Discovered in Mud Bacterium

Host defense peptides and their antimicrobial-immunomodulatory duality

Pretreatment with cathelicidin-BF ameliorates Pseudomonas aeruginosa pneumonia in mice by enhancing NETosis and the autophagy of recruited neutrophils and macrophages

Biofilm-related infections: Bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. Microbiol

Inhibition of bacterial biofilm formation and swarming motility by a small synthetic cationic peptide

Human host defense peptide LL-37 prevents bacterial biofilm formation

The co-evolution of host cationic antimicrobial peptides and microbial resistance

Antimicrobial Peptides as Potential Alternatives to Antibiotics in Food Animal Industry

Antimicrobial Activity of Small Synthetic Peptides Based on the Marine Peptide Turgencin A: Prediction of Antimicrobial Peptide Sequences in a Natural Peptide and Strategy for Optimization of Potency

Mechanisms of Action for Antimicrobial Peptides with Antibacterial and Antibiofilm Functions

The role of antimicrobial peptides in preventing multidrug-resistant bacterial infections and biofilm formation

Database of antimicrobial/cytotoxic activity and structure of peptides as a resource for development of new therapeutics

Romo1-Derived Antimicrobial Peptide Is a New Antimicrobial Agent against Multidrug-Resistant Bacteria in a Murine Model of Sepsis

Development of a novel hybrid antimicrobial peptide for targeted killing of Pseudomonas aeruginosa

Combating bacterial resistance by combination of antibiotics with antimicrobial peptides

Cerocin, a novel piscidin-like antimicrobial peptide from black seabass, Centropristis striata

Multiple action mechanism and in vivo antimicrobial efficacy of antimicrobial peptide Jelleine-I

A novel defensin-like peptide contributing to antimicrobial and antioxidant capacity of the tick Dermacentor silvarum (Acari: Ixodidae)

Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A

Antimicrobial Peptides Display Strong Synergy with Vancomycin against Vancomycin-Resistant E. faecium, S. aureus, and Wild-Type E. coli

Methicillin-Resistant Staphylococcus aureus: Molecular Characterization, Evolution, and Epidemiology

Molecular insight into how MRSA is becoming increasingly dangerous

Peptide-Mimicking Poly(2-oxazoline)s Displaying Potent Antimicrobial Properties

Interaction of the antimicrobial peptide ∆M3 with the Staphylococcus aureus membrane and molecular models

The antimicrobial peptide SAAP-148 combats drug-resistant bacteria and biofilms

Defining principles that influence antimicrobial peptide activity against capsulated Klebsiella pneumoniae

Antimicrobial activity of two novel antimicrobial peptides AA139 and SET-M33 against clinically and genotypically diverse Klebsiella pneumoniae isolates with differing antibiotic resistance profiles

Antimicrobial Activity of Selected Antimicrobial Peptides Against Planktonic Culture and Biofilm of Acinetobacter baumannii

Antimicrobial Peptide Cec4 Eradicates the Bacteria of Clinical Carbapenem-Resistant Acinetobacter baumannii Biofilm

Antimicrobial peptides as a promising treatment option against Acinetobacter baumannii infections

Identification of potential therapeutic antimicrobial peptides against Acinetobacter baumannii in a mouse model of pneumonia

The antimicrobial peptide ZY4 combats multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii infection

The antimicrobial peptide DGL13K is active against resistant gram-negative bacteria and subinhibitory concentrations stimulate bacterial growth without causing resistance

Antimicrobial peptide GL13K is effective in reducing biofilms of Pseudomonas aeruginosa

Aryl-Alkyl-Lysines Interact with Anionic Lipid Components of Bacterial Cell Envelope Eliciting Anti-Inflammatory and Antibiofilm Properties

Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens

Revealing the Mechanisms of Synergistic Action of Two Magainin Antimicrobial Peptides

In vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infections

Vitro Evaluation of Antimicrobial Peptide Tridecaptin M in Combination with Other Antibiotics against Multidrug Resistant Acinetobacter baumannii. Molecules

Antimicrobial peptides from hylid and ranin frogs originated from a 150-millionyear-old ancestral precursor with a conserved signal peptide but a hypermutable antimicrobial domain

In vitro activities of dermaseptins K4S4 and K4K20S4 against Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa planktonic growth and biofilm formation

Bacteriocin biosynthesis contributes to the anti-inflammatory capacities of probiotic Lactobacillus plantarum

Interaction of the cyclic antimicrobial cationic peptide bactenecin with the outer and cytoplasmic membrane

Evaluation of synergistic activity of bovine lactoferricin with antibiotics in corneal infection

Synergistic Nisin-Polymyxin Combinations for the Control of

Synergistic effect of two antimicrobial peptides, Nisin and P10 with conventional antibiotics against extensively drug-resistant Acinetobacter baumannii and colistin-resistant Pseudomonas aeruginosa isolates

The Antimicrobial Peptide Gad-1 Clears Pseudomonas aeruginosa Biofilms under Cystic Fibrosis Conditions. Chembiochem Eur

What is Preventive Medicine?

Polycationic peptides as prophylactic agents against methicillin-susceptible or methicillin-resistant Staphylococcus epidermidis vascular graft infection

Antibacterial Peptide-Based Gel for Prevention of Medical Implanted-Device Infection

Prevention of urinary catheter-associated infections by coating antimicrobial peptides from crowberry endophytes

Antimicrobial peptides for the prevention and treatment of dental caries: A concise review

Antimicrobial peptides prevent bacterial biofilm formation on the surface of polymethylmethacrylate bone cement

Bacterial Biofilm and its Role in the Pathogenesis of Disease

Biofilm formation mechanisms and targets for developing antibiofilm agents

The role of bacterial biofilms and surface components in plant-bacterial associations

Healthcare-associated infections, medical devices and biofilms: Risk, tolerance and control

Effect of vancomycin-coated tympanostomy tubes on methicillin-resistant Staphylococcus aureus biofilm formation: In vitro study

D-LL-31 enhances biofilm-eradicating effect of currently used antibiotics for chronic rhinosinusitis and its immunomodulatory activity on human lung epithelial cells

Kanthawong, S. D-LL-31 in combination with ceftazidime synergistically enhances bactericidal activity and biofilm destruction in Burkholderia pseudomallei

Antimicrobial d-Peptide Hydrogels

The synthetic antimicrobial peptide KLKL5KLK enhances the protection and efficacy of the combined DNA vaccine against Mycobacterium tuberculosis

Jonsdottir, I. IC31, a two-component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against pneumococcal disease in neonatal mice

The role of vaccines in combatting antimicrobial resistance

Antimicrobial Peptides and Vaccine Development to Control Multi-drug Resistant Bacteria

Antimicrobial Peptides as Probes in Biosensors Detecting Whole Bacteria: A Review

Antimicrobial peptides as infection imaging agents: Better than radiolabeled antibiotics

(99m) Tc-HYNIC/EDDA]-MccJ25 antimicrobial peptide analog as a potential radiotracer for detection of infection

Database of Antimicrobial Activity and Structure of Peptides

Manipulated bio antimicrobial peptides from probiotic bacteria as proposed drugs for COVID-19 disease

The Potential of Antiviral Peptides as COVID-19 Therapeutics

Brilacidin, a COVID-19 Drug Candidate

The Potential of Antimicrobial Peptides as an Antiviral Therapy against COVID-19

Silico Discovery of Antimicrobial Peptides as an Alternative to Control SARS-CoV-2

Very Short and Stable Lactoferricin-Derived Antimicrobial Peptides: Design Principles and Potential Uses

Correlation between hemolytic activity, cytotoxicity and systemic in vivo toxicity of synthetic antimicrobial peptides

Degradation of naturally occurring and engineered antimicrobial peptides by proteases

Differential stability of therapeutic peptides with different proteolytic cleavage sites in blood, plasma and serum

Mammalian Antimicrobial Peptides: Promising Therapeutic Targets Against Infection and Chronic Inflammation

Antimicrobial Peptides and Their Therapeutic Potential for Bacterial Skin Infections and Wounds

Antimicrobial Peptide-Functionalized Mesoporous Hydrogels

The Road from Host-Defense Peptides to a New Generation of Antimicrobial Drugs

Antimicrobial peptides-Advances in development of therapeutic applications

Gastric antimicrobial peptides fail to eradicate Helicobacter pylori infection due to selective induction and resistance

Bacterial strategies of resistance to antimicrobial peptides

The antimicrobial activity of the appetite peptide hormone ghrelin

Antimicrobial peptides under clinical investigation

Facile and efficient encapsulation of antimicrobial peptides via crosslinked DNA nanostructures and their application in wound therapy

Improved proteolytic stability of chicken cathelicidin-2 derived peptides by D-amino acid substitutions and cyclization

Nanoparticle-Loaded Hydrogel for the Light-Activated Release and Photothermal Enhancement of Antimicrobial Peptides

Improving Recognition of Antimicrobial Peptides and Target Selectivity through Machine Learning and Genetic Programming

Dimerization of Antimicrobial Peptide Polyphemusin I into One Polypeptide Chain: Theoretical and Practical Consequences

Selective amino acid substitution reduces cytotoxicity of the antimicrobial peptide mastoparan

Towards Robust Delivery of Antimicrobial Peptides to Combat Bacterial Resistance

Specifically targeted antimicrobial peptides: A new and promising avenue in selective antimicrobial therapy

Targeted Antimicrobial Peptides: A Novel Technology to Eradicate Harmful Streptococcus Mutans

The introduction of L-phenylalanine into antimicrobial peptide protonectin enhances the selective antibacterial activity of its derivative phe-Prt against Gram-positive bacteria

Analogs of the Cathelicidin-Derived Antimicrobial Peptide PMAP-23 Exhibit Improved Stability and Antibacterial Activity

Evaluation of the bioactivity of a mastoparan peptide from wasp venom and of its analogues designed through targeted engineering

We are grateful to N. D'Amelio for the helpful advice.

The authors declare no conflict of interest.Antibiotics 2021, 10, 1095